Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence.

Neuropharmacology

University of California, San Diego and Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive, MC116B, San Diego, CA 92161, United States.

Published: February 2012

AI Article Synopsis

  • Emerging research highlights that disrupted sleep is a key element of Posttraumatic Stress Disorder (PTSD), which can lead to significant distress and health issues.
  • Effective treatments for nighttime PTSD symptoms, including behavioral and pharmacological interventions, show potential, particularly for nightmares, but more controlled studies are needed to validate these findings.
  • A holistic approach that combines various treatment methods for both daytime and nighttime PTSD symptoms may enhance our effectiveness in addressing sleep disturbances related to the disorder.

Article Abstract

Emerging evidence supports the notion of disrupted sleep as a core component of Posttraumatic Stress Disorder (PTSD). Effective treatments for nighttime PTSD symptoms are critical because sleep disruption may be mechanistically linked to development and maintenance of PTSD and is associated with significant distress, functional impairment, and poor health. This review aimed to describe the state of science with respect to the impact of the latest behavioral and pharmacological interventions on posttraumatic nightmares and insomnia. Published studies that examined evidence for therapeutic effects upon sleep were included. Some behavioral and pharmacological interventions show promise, especially for nightmares, but there is a need for controlled trials that include valid sleep measures and are designed to identify treatment mechanisms. Our ability to treat PTSD-related sleep disturbances may be improved by moving away from considering sleep symptoms in isolation and instead conducting integrative studies that examine sequential or combined behavioral and/or pharmacological treatments targeting both the daytime and nighttime aspects of PTSD. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154613PMC
http://dx.doi.org/10.1016/j.neuropharm.2011.02.029DOI Listing

Publication Analysis

Top Keywords

nightmares insomnia
8
posttraumatic stress
8
stress disorder
8
behavioral pharmacological
8
pharmacological interventions
8
sleep
6
treating nightmares
4
insomnia posttraumatic
4
disorder review
4
review current
4

Similar Publications

Patients with obsessive-compulsive disorder are presumed to be at higher risk of sleep disorders due to the potential interference that persistent thoughts and compulsions may exert on sleep. Although there are studies on sleep findings in patients with obsessive-compulsive disorder, there are few systematic reviews on the presence of sleep disorders in patients with obsessive-compulsive disorder for adults and children. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines were followed to perform a comprehensive search of PubMed and Web of Science using the MeSH terms "obsessive-compulsive disorder" and "sleep wake disorders".

View Article and Find Full Text PDF

Background: There is a bidirectional relationship between sleep and pain disturbances. Sleep disturbances increase the risk for chronic pain, while chronic pain can interfere with sleep. Hence, we assessed the subjective sleep characteristics of youth with functional abdominal pain disorders (FAPDs) compared to healthy youth and examined associations with gastrointestinal symptoms.

View Article and Find Full Text PDF

Molecular Signaling Pathways of Quercetin in Alzheimer's Disease: A Promising Arena.

Cell Mol Neurobiol

December 2024

Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AlBeheira, Egypt.

Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and memory deficit. Even with extensive research and studies, presently, there is no effective treatment for the management of AD. Besides, most of drugs used in the treatment of AD did not avert the AD neuropathology, and the disease still in a progressive status.

View Article and Find Full Text PDF
Article Synopsis
  • * A patient with a family history of prion disease showed early signs of FFI, like sleep issues and cognitive problems, yet standard diagnostic tests (MRI, CSF analysis, EEG) did not reveal typical changes associated with prion diseases.
  • * Genetic testing confirmed the presence of a harmful mutation linked to FFI, leading to a swift decline in health and eventual death, highlighting the need for awareness among healthcare providers to enhance patient management and emotional support for those affected.
View Article and Find Full Text PDF

Aims: This systematic review and meta-analysis aimed to evaluate the association between β-blocker use and neuropsychiatric adverse events, specifically focusing on short-term outcomes.

Methods: A comprehensive literature search identified studies reporting neuropsychiatric outcomes in patients using β-blockers, including randomized controlled trials and observational studies. Relative risks (RR) and 95% confidence intervals (CIs) were calculated for outcomes such as dizziness, insomnia, nightmares, drowsiness and delirium.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!